Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jeunhui KimDepartment of Advanced Green Energy and Environment, Handong Global University, Pohang, South Korea.
HyunA JoCancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Juwon LeeCancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Untack ChoCancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Maria LeeDepartment of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea.
Cheol LeeDepartment of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Danny N DhanasekaranStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Taejin AhnResearch Group, Foretell My Health, Pohang, South Korea.
Yong Sang SongDepartment of Obstetrics and Gynaecology, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.ORCID 0000-0001-7115-4021
Funding
Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)Korean National Research Foundation 2019R1C1C1008185Republic of Korea HI16C2037
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Deep LearningOvarian NeoplasmsAntineoplastic AgentsCystadenocarcinoma, SerousFemaleHumansPrecision MedicineAntineoplastic Agents
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Tailored chemotherapy: Innovative deep-learning model customizing chemotherapy for high-grade serous ovarian carcinoma. · full record | OpenQuestion